Report #2842530

Received May 23, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Unknown
Age: Age unknown
State: NJ
Recovered: Unknown
Vaccinated: —
Onset: —
Days to onset: —
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	UNK	—	SC

Symptoms (1)

Incorrect route of product administration

Symptom narrative

tech giving a Shingrix vaccine subcutaneously; This non-serious case was reported by a other health professional via call center representative and described the occurrence of intramuscular formulation administered by other route in a patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received Shingrix (subcutaneous). On an unknown date, an unknown time after receiving Shingrix, the patient experienced intramuscular formulation administered by other route (Verbatim: tech giving a Shingrix vaccine subcutaneously). The outcome of the intramuscular formulation administered by other route was not applicable. Additional Information: GSK Receipt Date: 20-MAY-2025 A pharmacy intern called to inform about a pharmacy tech given a Shingrix vaccine subcutaneously, which led to an intramuscular formulation administered by other route. Reporter did not have information about other details concerned this incident.